Skip to content
Open access

CRYAB as a key mediator of Xianlian Jiedu Decoction-induced suppression of colorectal cancer stemness.

Oct 2026 · Journal of Ethnopharmacology · pp. 122585 · 0 citations · 59 references
Medicine

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE Xianlian Jiedu Decoction (XLJDD) has long been used clinically in the treatment of colorectal cancer (CRC). Our preliminary work indicated that XLJDD exerts anti-CRC activity by attenuating inflammation, restoring gut microbiota balance, and modulating signaling pathways such as CXCR2/PI3K/AKT. However, the bioactive constituents and the precise molecular mechanisms underlying these effects remain poorly defined. The present study sought to clarify the active components and mechanisms of XLJDD in CRC, thereby providing a scientific basis for its further therapeutic application.

Aim

OF THE STUDY This study aimed to investigate the inhibitory effect of XLJDD on tumor stemness in CRC and to elucidate the underlying molecular mechanisms.

Materials And Methods

An orthotopic CRC mouse model was established and treated with XLJDD for 21 days. The chemical constituents of XLJDD were characterized by UPLC-MS/MS, and treatment-related metabolic alterations were profiled by plasma metabolomics. Tumor tissues were subjected to single-cell RNA sequencing to identify differentially expressed genes, which were validated by Western blot and immunohistochemistry. In vitro, HCT116 and HT29 cells were evaluated for proliferation, sphere-forming capacity, stemness-marker (CD44/CD133) populations by flow cytometry, and protein expression by Western blot. CRYAB-knockdown cell lines were generated to assess proliferation (CCK-8), apoptosis, cell-cycle distribution, and stemness-marker expression. Transcriptome sequencing combined with Ingenuity Pathway Analysis (IPA) was performed across treatment groups (NC, NC+XLJDD, CRYAB-KD, CRYAB-KD+XLJDD) to define the downstream signaling pathways regulated by XLJDD.

Results

XLJDD significantly suppressed tumor growth in the orthotopic CRC model. Plasma metabolomics revealed clear separation between groups, with reduced phenylalanine and glycerophospholipid metabolism and enhanced energy metabolism in XLJDD-treated mice. Single-cell RNA sequencing of tumors identified cancer-cell clusters with high CRYAB and ALDH3A1 expression that were markedly suppressed following XLJDD treatment. In vitro, XLJDD reduced proliferation, sphere formation, CD44+/CD133+ populations, and stemness-marker expression. CRYAB knockdown impaired proliferation, induced apoptosis and G1-phase arrest, and attenuated stem-like features in CRC cells. Transcriptomic profiling with IPA identified STC1 as a downstream target of CRYAB, with the CRYAB-STC1 axis closely linked to the core stemness transcription factors OCT4, SOX2, and NANOG.

Discussion

These findings indicate that XLJDD constrains CRC stemness through a CRYAB-driven regulatory program rather than a single isolated target. By coupling CRYAB to STC1 and the OCT4/SOX2/NANOG network, the study connects XLJDD's anti-tumor activity to a defined stemness axis and positions CRYAB as a tractable node within it. Because CRYAB knockdown both reproduced and reinforced the anti-stemness effect of XLJDD, the data suggest that XLJDD acts, at least in part, by downregulating CRYAB, offering a mechanistic rationale that extends beyond its previously reported anti-inflammatory and metabolic effects.

Conclusion

This study demonstrates for the first time that XLJDD suppresses CRC tumor stemness by targeting the CRYAB-STC1 axis. By integrating metabolomics, single-cell transcriptomics, and functional validation, this work provides new evidence that XLJDD regulates cancer stemness and offers experimental support for its therapeutic potential in CRC.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.